Lyme Disease Diagnostics Market - Competitive Analysis with Forecast 2021-2031

Lyme Disease Setting Record in Number of Cases Every Year

Lyme disease is the most prevalent vector-borne disease across the world. It is caused by the bacterium Borrelia burgdorferi and sometimes, Borrelia mayonii. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks.

Lyme disease diagnostics measure Borrelia immunizers in the blood, or the cerebrospinal fluid (CSF) to identify the signs and symptoms of central nervous system disease. The surge in the frequency and prevalence of Lyme disease and rising investments from government organizations and large corporates for developing diagnostic kits are primary reasons contributing to the growth of the global Lyme disease diagnostics market.

Healthcare organizations such as CDC suggests two methods to identify these immunizers or antibodies to confirm a diagnosis of Lyme disease. The first diagnosis use practices such as an enzyme immunoassay (EIA) or immunofluorescence (IFA) method to measure Borrelia IgM and/or IgG antibodies. This diagnosis is intended to be very sensitive so that it will detect as many cases of Lyme disease as possible.

Get Sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1658

The results may be positive even with similar types of bacteria such as the different tick-borne disease or syphilis or in other conditions, such as Lupus. The second diagnosis is recommended after the test of initial diagnosis with positive or indeterminate results. It is called a Western Blot that detects specific antibodies to multiple antigens to confirm the findings.

Lyme disease cases are presently crossing the 400,000 mark every year in U.S. alone, and the need for diagnosis of these patients is rapidly increasing, thus proving propitious for the global Lyme disease diagnostics market.

Similarities Between Borrelia Burgorferi, SARS-CoV-2 Proving Challenging for Experts

The worldwide COVID-19 pandemic has eclipsed the attention of healthcare professionals, affecting all areas of health and diagnostics care. The crisis has had several indirect health effects as well.

The concern among individuals for the infection has decreased outpatient visits with healthcare providers. Symptomatic patients may be considered to have COVID-19 until negative test results are received, implying that evaluations for other diseases will be delayed, potentially leading to adverse outcomes.

People with Lyme disease symptoms were asked to postpone their tests, as the coronavirus spread began to take over the world. People were recommended to be in quarantine as evaluation for other causes of the patient's symptoms other than the COVID-19 virus was often deferred, risking delayed diagnosis and complications.

Moreover, as Lyme and COVID-19 virus often start with non-specific flu-like symptoms with fever, headache, and general achiness and fatigue, it made patients and medical experts more concerned about both infections in individuals.

Request Report Methodology@ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=1658

Thus, patients were suggested to diagnose with the available medical institutions helping to diagnose other diseases.

The impact of this dramatic change in healthcare provision is only opening to be recognized, but includes decreased ambulatory visits with outpatient providers, hampering the growth of the global Lyme disease diagnostics market.

In addition, the COVID-19 crisis has led to the adoption of telemedicine for the delivery of healthcare in many developed regions including North America and Europe. However, the impact of telemedicine on the diagnosis of acute infectious diseases such as Lyme disease is still under observation.

Furthermore, misdiagnosis and delays in diagnosis of Lyme disease can potentially result in bacterial dissemination and involvement of distant organ systems, most importantly the neurologic, cardiac, and musculoskeletal systems. The neurologic association normally exhibits after the first few weeks of untreated virus and can result in meningitis, cranial nerve palsy, and radiculoneuritis.

Post-COVID, however, there is likely to be a significant increase in the diagnosis of Lyme disease, as the number of vaccination is increasing, most people can feel safe to visit a diagnostics center. This is expected to propel the Lyme disease diagnostics market.

New Ways to Diagnose Lyme Disease to Drive Global Demand for Diagnostics

The advancement in research and diagnosis of a new cytokine-based immunoassay for Lyme diagnosis can allow for earlier and more rapid diagnosis of the Lyme disease, if successful. Numerous researchers are working on the progress of a new, rapid point-of-care Lyme diagnostic test using lateral flow technologies.

Metabolic biomarkers and biosignatures for enhanced diagnostics are being recognized and defined. All these studies are expected to contribute to new ways for identifying the Lyme disease, earlier-stage diagnosis, accurate staging of disease, or indications of successful treatment. This is anticipated to fuel the growth of the Lyme disease diagnostics market.

Read Report Overview@ https://www.transparencymarketresearch.com/lyme-disease-diagnostic.html

The advancements in the Lyme disease diagnostics portfolio by several major businesses have welcomed the approval by launching innovative Lyme disease diagnostics. T2 Biosystems developed a T2Lyme Panel diagnostic technique for the detection of Lyme disease-causing bacteria. Such innovations are likely to fuel the demand for upgraded Lyme disease diagnostics, thus driving the Lyme disease diagnostics market.

In the initial stages of diagnosis, researchers can now look at other molecules that arise earlier in infection instead of waiting for the antibodies creation in the blood. The experts are examining the pattern of a host of non-antibody molecules, or biomarkers that rise in response to B.

burgdorferi infection, as compared to the pattern in other disease overlapping symptoms with Lyme disease. The pattern distinguishes early Lyme disease from the different illnesses examined, and could precisely diagnose the disease even in clinical samples that had tested negative by the current immunologic assay. In most cases, antibiotics are used to treat Lyme disease.

It can help recover quickly and more completely the sooner the treatment begins.

Get Customization Research on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1658

Furthermore, North America holds the most number of major diagnostics centers and key market players. Rising healthcare expenditure, early availability of new products, and major patient base in the U.S. are expected to dominate the regional shares in the Lyme disease diagnostics market during the forecast period.

Lyme Disease Diagnostics Market: Overview

• Lyme disease, commonly known as Lyme borreliosis, is an infectious disease that is caused by Borrelia bacteria and carried by ticks. The most typical indication of infection is the spreading red rash, known as erythema migrans, which emerges around a week after tick bite.

• Blood, cerebrospinal fluid (CSF), joint fluid, and urine are used for the diagnosis of Lyme disease

• The global Lyme disease diagnostics market has experienced significant growth in the past decade due to increase cases of Lyme disease

• Various diagnostic tests are available for the detection of Lyme disease, including serological test, polymerase chain reaction (PCR) testing, immunofluorescence (IFA), lymphocyte transformation test, urine antigen testing, and others

• Increase in incidences and prevalence of Lyme disease drive the demand for Lyme disease diagnostics. Lyme disease is a highly common vector-borne disease in the U.S. and across the globe, with over 400,000 new cases every year. Only a few tests are available in the market that accurately diagnose Lyme disease. Moreover, frequent mutations and genotypic variations in the causative bacteria increase the prevalence among the global population.

Make an Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1658

• Need of development of novel therapy has increased due to various disadvantages associated with conventional and regular traditional techniques such as lack of accuracy, precision, and reproducibility

• Various research institutes, organizations, and healthcare companies are engaged in finding a better technology for the diagnosis of Lyme disease, which, in turn, drives the global Lyme disease diagnostics market

• Expansion of Lyme disease diagnostics portfolio by key companies boosts the approval and launch of innovative Lyme disease diagnostics. In September 2018, T2 Biosystems, Inc. developed T2Lyme Panel diagnostic technique for detection of Lyme disease-causing bacteria.
Market Segmentation: Lyme Disease Diagnostics Market

• In terms of diagnostic test, the global Lyme disease diagnostics market has been classified into serological test, polymerase chain reaction (PCR) testing, immunofluorescence (IFA), lymphocyte transformation test, urine antigen testing, and others. The serological test segment has been split into ELISA and Western blot. The serological test segment is anticipated to dominate the global Lyme disease diagnostics market during the forecast period.

• Based on sample, the global Lyme disease diagnostics market has been categorized into blood, cerebrospinal fluid (CSF), joint fluid, and urine. The blood segment dominated the global Lyme disease diagnostics market in terms of revenue in 2020.

• In terms of end user, the global Lyme disease diagnostics market has been divided into hospitals, clinical laboratories, physician clinics, and others. The clinical laboratory segment dominated the global Lyme disease diagnostics market in terms of revenue in 2020.

• Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Mn) for each of these segments from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Ask an References@ https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=1658

Regional Overview: Lyme Disease Diagnostics Market

• In terms of region, the global Lyme disease diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

• Current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2017 to 2031, with their CAGRs from 2021 to 2031

• The study also offers a list of
recommendations, highlights, and useful insights of the global Lyme disease diagnostics market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process
Major Players

• The Lyme disease diagnostics market report concludes with the company profiles section, which includes key information about major players in the global Lyme disease diagnostics market

• Leading players analyzed in the Lyme disease diagnostics market report include

o T2 Biosystems, Inc.
o QIAGEN
o DiaSorin S.p.A
o Bio-Rad Laboratories
o Thermo Fisher Scientific, Inc.
o Trinity Biotech plc
o IGeneX Inc.
o Lyme Diagnostics Ltd.
o PerkinElmer Inc.
o Oxford Immunotec plc (Boulder Diagnostics)
o Cenogenics Corporation
o Quest Diagnostics
o Ceres Nanosciences, Inc.
o Galaxy Diagnostics

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services.. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.